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EDITORIAL COMMENT
Mindfully Mining MUSTT*
Jay W. Mason, MD, FACC
Lexington, Kentucky
In this issue of the Journal the MUSTT (Multicenter
Unsustained Tachycardia Trial) investigators (1), extend
their post hoc analyses of the original trial. By comparing
outcomes of those patients in the EP group (patients
discharged on drugs predicted effective by electrophysio-
logic testing) who received implanted cardioverter defibril-
lators (ICDs) to those randomized to no antiarrhythmic
therapy, the investigators conclude that electrophysiologic-
pharmacologic study (EPS) provides no benefit in patients
with spontaneous-unsustained, and inducible-sustained
ventricular tachycardia associated with coronary artery dis-
ease (CAD) and impaired left ventricular (LV) function.
The primary analysis in the original report of MUSTT
(2) showed that the EP patients did obtain a survival
benefit. In that report the investigators performed a post hoc
analysis by separately examining outcomes in patients in the
EP group that did and did not receive ICDs. The analysis
showed that the survival advantage in the EP group was
apparently exclusively due to ICDs, as those who did not
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receive them, and thus were treated only with antiarrhyth-
mic drugs, had a poorer outcome than did those who
received ICDs. They concluded that electrophysiologically
selected antiarrhythmic therapy per se did not account for
improved outcome in the EP group, but, rather, that ICDs
did.
In the current study (1), the MUSTT investigators
further explore the influence on outcome of drugs selected
by EPS. They employ actuarial analyses similar to those
used in the original study (2) to compare treatment groups,
with one major difference: in the current study they censor
patients when they receive an ICD. The intent is to remove
the influence of ICDs so that the survival effect of drugs
selected by EPS could be isolated. The analysis shows no
difference in survival in patients without ICDs who were
treated with drugs selected by EPS compared to those who
received no antiarrhythmic therapy. A subanalysis of specific
drugs does not appear to demonstrate a statistically signif-
icant difference in outcome among the drugs, although there
was a large spread in actuarial survival at two years (as
estimated from the actuarial plots): sotalol, 76% (n 5 30);
class IA 1 others, 71% (n 5 88); propafenone, 50% (n 5
13); amiodarone, 45% (n 5 21). Interestingly, sotalol was
also found to be superior to class IA and IC drugs in the
Electrophysiologic Study Versus Electrocardiographic
Monitoring (ESVEM) study (3).
A post hoc analysis is one that was not planned prior to
initiation of a trial. Clinical trials are designed to answer one
or a few questions. The number of subjects recruited to the
trial, their clinical characteristics and the conduct of the trial
from start to finish are constructed to address one or a few
primary hypotheses specifically. Analyses that were not
incorporated into the original trial design may lead to
important findings and should be undertaken. However,
these post hoc analyses should be interpreted cautiously and
should not, except in unusual cases, be relied upon to
establish new guidelines for clinical care. You might argue
that statistics take care of this problem, that any statistically
significant finding is valid and reliable. Isn’t that what
statistics are for? No.
Statistical methods are mathematically complex and so-
phisticated, but they are incapable of shielding against biases
that may influence results. Trial design must do that. In
clinical trials, investigator bias is assiduously avoided by
randomization and blinding procedures. There are three
types of bias to consider. The first bias is in trial design,
favoring one outcome over another. The second is bias of
investigators, resulting in differential management of treat-
ment groups. The third bias is in reporting. All three types
of bias are evident in the conduct and analyses of MUSST.
This does not constitute a criticism. Bias affects many
clinical trials, usually without investigator intent; however, it
is important to recognize its presence to understand fully a
trial’s results.
Trial design bias is well illustrated by the midcourse
change in the MUSTT protocol. After enrollment of
approximately one-half of the final patient sample, the
protocol was changed to allow ICDs in the EP group after
a single drug failure. Prior to that change, patients had been
required to fail to respond to three drugs at EPS before
receiving an ICD. Trials often must adapt to changes in
medical knowledge and practice. The change made in the
MUSTT protocol was necessary because of a growing
preference that developed among physicians while the trial
was in progress to use ICDs rather than antiarrhythmic
drugs. This preference initially evolved as a result of spec-
tacular technical improvements in ICDs, which allowed
minimally invasive implantation and marked reduction in
inappropriate shock delivery.
At about the same time, three trials were published that
reduced confidence in use of EPS for selection of drug
therapy in patients with ventricular tachyarrhythmias (4–6).
Also, the shortcomings of antiarrhythmic therapy were
highlighted in several trials that demonstrated their inability
to prevent sudden death (7–10). The investigators were
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forced to revise the protocol so as to make it more consistent
with current clinical practice and to encourage enrollment
into the trial. As a result of the midcourse change, MUSTT,
in essence, became a device efficacy trial rather than a study
of the efficacy of electrophysiologically selected drugs in
primary prevention of sudden death. The trial had not been
designed for that purpose, and, in fact, its original hypoth-
esis could no longer be tested because the protocol change
resulted in the implanting of ICDs in the majority of
patients in the EP group (161 of 319 discharged patients).
The EP group was no longer an antiarrhythmic drug-
treated group as originally intended (11). Instead, the main
finding of the study had to be provided by a post hoc
analysis. This, then, is a clear example in which design bias
changed the outcome of a clinical trial. We cannot easily use
statistics to remove that bias, although the investigators
attempt to do so in the current analysis (1), which addresses
the original hypothesis.
The second type of bias, differential management of
patients in separate treatment limbs, is also evident in
MUSTT. Why did 41 patients in the EP group, but only,
at most, 11 in the control group, receive ICDs during
follow-up after hospital discharge? At least 339 control
patients, compared with only 158 in the EP group, began
follow-up without an implanted device. Because more than
twice as many control patients could have received an ICD
if an arrhythmia event mandated therapy, there was, in
effect, an eightfold greater rate of ICD implantation during
follow-up in the EP group. I assume that indications for
adding a new antiarrhythmic therapy during follow-up were
absolute, applying equally to patients in both limbs. Clinical
characteristics of the patients in the EP group and the
control group were the same, as provided by the random-
ization process. Arrhythmia recurrence rates in follow-up
would be expected to be similar in the two groups, unless
the therapies had differing efficacy. Because the original
report (2) showed only a modestly higher incidence of
arrhythmia recurrence in the drug-treated patients without
ICDs, that certainly cannot account for an eightfold greater
rate of device implantation. Could antiarrhythmic drug
intolerance account for the eightfold difference? Only if
both of two unlikely conditions pertained: intolerance oc-
curred at a rate inexplicably greater than usual for the drugs
used in MUSTT, and all alternate antiarrhythmic drugs
were also not tolerated. The original null hypothesis of the
trial was that electrophysiologically guided therapy and no
therapy were equivalent. Well before the conclusion of the
trial it appears that some investigators had not only made up
their minds that therapy was better than no therapy, but
they had also decided which specific therapy (ICDs) was
better. That bias strongly influenced the subsequent conduct
of the trial.
A feature of trial design may have introduced another
instance of differential treatment bias. Because of the change
in protocol permitting increased ICD use, the nature of
follow-up care became, necessarily, more intense in the EP
group, because most of those patients required periodic
defibrillator checks. They had to be seen by cardiac arrhyth-
mia specialists, and those specialists were provided, through
device interrogation, with arrhythmia data unavailable to
physicians managing patients without ICDs. Could this
higher intensity of care and clinical information have
improved outcome in the EP group independently of the
therapeutic effect of ICDs?
Potential reporting bias is implicit in the post hoc analysis
presented in the current study (1). The preplanned analysis
was an intention-to-treat comparison of the entire EP and
control groups. This implies a primary interest in evaluating
efficacy of a clinical practice pathway in which the initial
therapy to which a patient is assigned is viewed as the first
step in a treatment strategy that may include additional or
alternative therapies as needed during follow-up. Here the
question is: “How does this initial therapy influence long-
term results, regardless of whether or not the therapy is
continued?” This is the usual and most appropriate question
asked in clinical trials. An analysis only of patients who
continue taking the original therapy is less reliable, espe-
cially when a large proportion of subjects drop out.
You may say, “So what? The trial has shown us the
truth—ICDs are effective and better than drugs in prevent-
ing death in patients with asymptomatic, unsustained ven-
tricular tachycardia associated with coronary disease and
impaired LV function.” Are you sure? Surprisingly, the new
analysis in this issue (1) provides a suggestion that this may
not be uniformly true. At two years the actuarial survival of
patients randomized to sotalol, with follow-up censored in
those who received ICDs, was 76%. Using data from the
original and current studies it is possible to roughly estimate
an additional survival benefit provided by ICDs in patients
receiving antiarrhythmic drugs selected by EPS in MUSTT.
Figure 1A in the current study (1) shows actuarial survival of
68% at two years in patients receiving EPS-selected antiar-
rhythmic drugs with censoring on receipt of an ICD. In
Figure 2 of the original report (2) the corresponding
estimate is 78% without censoring of follow-up after ICD
placement. Comparison of these two rates suggests that the
ICD adds 10% to the two-year actuarial survival of patients
assigned to antiarrhythmic therapy by EPS. (Parenthetical-
ly, survival at two years in the no-therapy group was 72%,
both with and without censoring at the time of device
implantation. Few patients in that group had received
ICDs.) If we now add this 10% increment to the two-year
survival of patients receiving sotalol alone, we estimate a
survival of 86% at two years for patients assigned to sotalol
and with access to ICD therapy if needed. This survival rate
is little different from the 89% survival of the original
EP-ICD group (2).
My analysis is an overly aggressive mining of data. As
merely another post hoc analysis, it, like all such analyses,
should only be used to generate ideas for future evaluation
and should not be used to establish treatment guidelines.
The analysis suggests that a treatment strategy that calls for
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initial use of sotalol, if predicted effective by EPS, with
addition of an ICD if indicated during follow-up, might be
as effective as that recommended by the investigators, who
state in their conclusions that antiarrhythmic drug therapy is
a secondary alternative for most patients, and ICD therapy
should be considered early.
The study of Wyse et al. (1) in this issue of the Journal is
an interesting exploratory analysis. I do not believe it should
prompt a change in clinical practice. Rather, it suggests a
need for a future trial to examine alternatives to immediate
device implantation. Prevailing interpretations of MUSTT
and the Multicenter Automatic Defibrillator Implantation
Trial (MADIT) (12) hold that patients with postinfarction
LV dysfunction and unsustained ventricular tachycardia
should receive ICDs if they have sustained ventricular
arrhythmia inducible by programmed ventricular stimula-
tion. Based upon data from MUSTT, as well as the recently
reported Amiodarone vs. Implantable Defibrillator in Pa-
tients with non-Ischemic Cardiomyopathy and Asymptom-
atic nonsustained Ventricular Tachycadia (AMIOVIRT)
trial, which failed to show superiority of ICDs over amio-
darone in patients with unsustained ventricular tachycardia
related to dilated cardiomyopathy (13,14), a study that
directly compared initial therapy with an ICD to initial
therapy with sotalol or amiodarone in patients fitting
MUSTT enrollment criteria would be helpful. The intensity
of follow-up care and data collection in these two groups
should be made as equal as possible. Many practicing
physicians, and patients, hesitate to embark upon relatively
aggressive, expensive, lifelong therapy based upon projected
risk rather than symptoms. Furthermore, ICDs are not
readily available in many countries. If a simpler initial
preventive therapy were demonstrated to be effective, more
patients would have access to it throughout the world and a
larger number would benefit.
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